Clinical Trial Update: eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 3]

View source ↗

Summary

Update on the Phase 3 eXalt3 trial comparing Ensartinib (X-396) to Crizotinib in ALK-positive non-small cell lung cancer, with the study currently not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• Ensartinib (X-396) (Ensartinib)

Snippet

Sponsor: Xcovery Holdings, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING